Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab (MK-3475) in Chinese Participants With Non-Small-Cell Lung Cancer (MK-3475-032/KEYNOTE-032)

Name: Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab (MK-3475) in Chinese Participants With Non-Small-Cell Lung Cancer (MK-3475-032/KEYNOTE-032)
Published: 2016
License: Public Domain

Merck Sharp & Dohme LLC · 2016

ClinicalTrials.gov · Datasets · License: Public Domain · 2016

Open Source ↗

non-small-cell-lung-cancer

non-small-cell lung cancer, programmed cell death 1 (pd-1, pd1), programmed cell death ligand 1 (pd-l1, pdl1), programmed cell death ligand 2 (pd-l2, pdl2), interventional, phase1

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab (MK-3475) in Chinese Participants With Non-Small-Cell Lung Cancer (MK-3475-032/KEYNOTE-032)

Related documents